



News Release

Suven Life secures three (3) Product Patents in China, Eurasia and Hong Kong

HYDERABAD, INDIA (March 14, 2016) – Suven Life Sciences Ltd (Suven) announces today that the grant of one (1) product patent from China (CN103380131), one (1) product patent from Eurasia (9 Countries) (22043) and one (1) product patent from Hong Kong (HK 1180955)) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2032.

The granted claims of the patents include **the class of selective 5-HT4 compounds** and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

With these new patents, Suven has a total of **twenty (20) granted patents from China, sixteen (16) granted product patents from Eurasia and nineteen (19) granted product patents from Hong Kong**. These granted patents are exclusive intellectual property of Suven and are achieved through the **internal discovery research** efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. **Suven has 3 clinical stage compounds, a Phase-2 initiated candidate SUVN-502, Phase- 1 completed candidate SUVN-G3031 and Phase-1 undergoing candidate SUVN-D4010 for Alzheimer's disease and Schizophrenia. In addition to that the Company has ten (10) internally-discovered therapeutic drug candidates currently** in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.

For more information please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;